BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 24162815)

  • 1. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
    Vaishnavi A; Capelletti M; Le AT; Kako S; Butaney M; Ercan D; Mahale S; Davies KD; Aisner DL; Pilling AB; Berge EM; Kim J; Sasaki H; Park S; Kryukov G; Garraway LA; Hammerman PS; Haas J; Andrews SW; Lipson D; Stephens PJ; Miller VA; Varella-Garcia M; Jänne PA; Doebele RC
    Nat Med; 2013 Nov; 19(11):1469-1472. PubMed ID: 24162815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
    Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
    Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
    Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
    Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
    Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
    J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
    Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic rearrangements of the NTRK1/NGF receptor.
    Pierotti MA; Greco A
    Cancer Lett; 2006 Jan; 232(1):90-8. PubMed ID: 16242838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPS15-NTRK1: a novel NTRK1 oncogenic fusion in patient with lung adenocarcinoma.
    Yang S; Li L; Chen D; Xiao M; Xian L
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3389-3392. PubMed ID: 33037466
    [No Abstract]   [Full Text] [Related]  

  • 17. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
    Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
    Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
    Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
    Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.